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Abstract
Background: As the incidence of stroke has increased, its impact on society has increased accordingly, while it 
continues to have a major impact on the individual. New strategies to further improve the quality, efficiency and 
logistics of stroke services are necessary. Early discharge from hospital to a nursing home with an adequate 
rehabilitation programme could help to optimise integrated care for stroke patients.
The objective is to describe the design of a non-randomised comparative study evaluating early admission to a nursing
home, with multidisciplinary assessment, for stroke patients. The study is comprised of an effect evaluation, an
economic evaluation and a process evaluation.
Methods/design: The design involves a non-randomised comparative trial for two groups. Participants are followed 
for 6 months from the time of stroke. The intervention consists of a redesigned care pathway for stroke patients. In this 
care pathway, patients are discharged from hospital to a nursing home within 5 days, in comparison with 12 days in the 
usual situation. In the nursing home a structured assessment takes place, aimed at planning adequate rehabilitation. 
People in the control group receive the usual care. The main outcome measures of the effect evaluation are quality of 
life and daily functioning. In addition, an economic evaluation will be performed from a societal perspective. A process 
evaluation will be carried out to evaluate the feasibility of the intervention as well as the experiences and opinions of 
patients and professionals.
Discussion: The results of this study will provide information about the cost effectiveness of the intervention and its 
effects on clinical outcomes and quality of life. Relevant strengths and weaknesses of the study are addressed in this 
article.
Trial registration: Current Controlled Trails ISRCTN58135104
Background
By the year 2020, 250 per 100,000 patients in the Nether-
lands will suffer from a stroke, and in many instances this
will result in permanent disabilities and handicaps[1].
Substantial evidence is available showing that hospital
stroke units reduce mortality, dependence and institu-
tionalisation[2] and that better outcomes are associated
with comprehensive and early assessment of stroke
patients[3]. It is also suggested that organised integrated
stroke care and the use of early supported discharge ser-
vices for stroke patients are less expensive than general
medical care, due to a reduction in hospital stay[4,5].
However there are very few data on the cost effectiveness
of integrated stroke care from a societal point of view[6].
In the Netherlands 32% of stroke patients return
directly to their home after hospital stay, 9% are dis-
charged to a rehabilitation centre and 31%, mainly elderly
stroke patients, are discharged to a nursing home for
rehabilitation[7]. Consequently, contrary to nursing
homes in many other countries, Dutch nursing homes
fulfil an important role in the rehabilitation of stroke
patients[8]. The mean duration of hospital stay of stroke
patients in 2004 was 12.6 days[9]. Demographic develop-
ments, the increased incidence and prevalence of stroke,
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the emergence of disease management programs, and
changes in the structure of the Dutch health care system
have led to new strategies to further improve the quality,
efficiency and logistics of care processes. Optimizing
stroke services involves: a) faster admission of stroke
patients to the hospital, leading to improved chances for
effective intervention, b) early discharge from hospital,
with an adequate plan for rehabilitation and c) improving
care after discharge to home.
In 2006, these developments led to a redesign of the
Stroke Service Maastricht Heuvelland. The essentials of
this redesign are: stroke patients are admitted to Maas-
tricht University Medical Centre for a maximum of 5 days
for diagnosis, early intervention and stabilization, after
which they are discharged to a special assessment and
rehabilitation ward in a nursing home. In this nursing
home, stroke patients undergo a structured multidisci-
plinary assessment, lasting a maximum of 5 days, and
take part in their first rehabilitation activities. During
assessment, the appropriate follow-up treatment is deter-
mined. Patients are then admitted to the follow-up set-
ting for rehabilitative care. This means discharge to either
their own home situation, to a specific rehabilitation hos-
pital, or continued stay in the nursing home for pro-
longed rehabilitation or continuing stay.
Cost effective integrated stroke care requires a high
degree of coordination between professionals in hospi-
tals, nursing homes and home care, a high quality integral
assessment in the nursing home and a system of ade-
quately timed patient transitions.
The principal expectation is that the redesigned pro-
cess of the Stroke Service Maastricht Heuvelland will lead
to cost effective care, with expected improvement in the
quality of care as well.
This article describes the design of a longitudinal com-
parative study, evaluating the cost effectiveness of an
early discharge to and assessment of stroke patients in a
nursing home, as part of a redesigned integrated stroke
care programme, in comparison with a comparable
stroke service region, where the redesign has not been
implemented.
The research questions in this study are:
1. What is the effect of early admission to and assess-
ment in the nursing home on functional outcomes,
quality of life, and satisfaction with care in compari-
son with the usual care provided by a stroke ser-
vice?[Effect evaluation]
2. From a societal perspective, what is the incremental
cost effectiveness of early admission to and assess-
ment in the nursing home, in comparison with the
usual care provided by a stroke service?[Economic
evaluation]
3. Research questions for the process evaluation
a) Is the new care pathway executed on time
according to the protocol?[Process evaluation]
b) What are the experiences and opinions of
patients and professionals about the newly devel-
oped care pathway?[Process evaluation]
Methods/Design
Study Design
We will conduct a comparative study with retrospective
and prospective parts, in which we will compare the rede-
signed stroke service in the intervention region with a
comparable region that offers the usual stroke care.
Ethical approval and informed consent
The Medical Ethical Committee of the University of
Maastricht has granted ethical approval. The trial is reg-
istered as ISRCTN58135104.
An information brochure will be given to all eligible
patients. At inclusion, patients will be informed person-
ally and also by means of written information on all
aspects of the project. The privacy of the participating
patients is protected, and all data will be coded and pro-
cessed anonymously. It will be made clear in the informed
consent form that each patient can terminate his or her
participation in the trial at any moment without the care
being influenced.
Study population
The patient population consists of consecutive stroke
patients who are admitted to the hospitals in both
research regions during a period of 18 months. The diag-
nosis of stroke will be made by a neurologist based on
patient history, physical examination and neuro-imaging.
Patients will be eligible to participate if they meet the fol-
lowing criteria: over 18 years of age and fluent in Dutch.
Exclusion criteria are: a life expectancy of less then a few
days, a previous diagnosis of dementia, hospital discharge
to home within a few days and occurrence of complica-
tions which require prolonged hospital care. Patients suf-
fering a recurrent stroke during their participation in this
study will not be asked to participate a second time.
Sample Size
The primary goal of this study is to achieve cost reduc-
tion without loss of quality of life. Based on an earlier
study among stroke patients[10], we estimate a difference
in utilities indicating health related quality of life between
the 2 regions. In this earlier study by Olsen, the utility dif-
ference based on the EuroQol was 0.11. Based on a power
of 80%, alpha 0.05, our study will need a sample size of
111 participants per group.
We expect a 25% drop-out of patients between inclu-
sion and the follow-up meeting 26 weeks later, due to pre-
mature termination of the trial participation, inability to
cooperate in the trial, or mortality[11]. To correct for thisHeijnen et al. BMC Public Health 2010, 10:279
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expected drop-out, the number of patients included will
be increased to 139 participants per group.
Intervention
The intervention (figure 1) consists of the execution of a
redesigned care pathway for stroke patients admitted to
the Maastricht University Medical Centre. Every patient
with a suspected stroke will be analysed in the emergency
ward. In case of a stroke, the patient will be admitted to
the stroke unit of the hospital, where, if indicated, throm-
bolysis will be followed by further diagnosis and treat-
ment. The new aspect of the critical care pathway
consists of a strict discharge regime in the neurology
department of the hospital. All necessary testing and
treatment in the hospital can be performed within 5
admission days, after which patients may be discharged if
medically stable. The underlying assumption for the
design is that hospitals are specialized in acute care and
treatment and do not provide optimal rehabilitation facil-
ities. From a cost effectiveness point of view as well, it
seems more appropriate to provide rehabilitation in a
centre specialised for this purpose.
In the redesigned care pathway, after 5 days all stroke
patients are discharged to a nursing home with a special-
ised assessment unit, resulting in a tailored rehabilitation
programme. Only patients who can be discharged
directly to their home within five days, or patients with
complications requiring prolonged hospital care, will not
be referred to the specialised nursing home unit. The
nursing home physician examines each patient immedi-
ately on arrival in the nursing home and initiates the
assessment program. In this program a multidisciplinary
team, consisting of a psychologist, physiotherapist, occu-
pational therapist, speech therapist, and trained nurses,
examine the patient by means of a structured assessment
protocol. Following assessment, the team will meet
within five days of the patient's admission to make rec-
ommendations for the best rehabilitation program. Their
advice will be based on admission and discharge criteria
formulated by the various care providers participating in
the stroke service. A structured possibility for the nursing
home physician to consult a rehabilitation physician, if
needed, is arranged. After the multidisciplinary meeting
the patient and his family will be informed about the pro-
posed rehabilitation track and after their approval this
track can be started.
There are three options for rehabilitation after the
assessment.
Figure 1 Flowchart of the study.
Usual Care Group
Inclusion of 139 
patients
Intervention Group
Hospital 
Stroke Unit
Home
Nursing Home
Rehabilitation 
Centre
Ultimate Destination 
(Home,Resident Home, 
Nursing Home)
Nursing Home 
Assessment Unit
Stroke T0 T1 T2 T3
Timeline of measurements
Inclusion of 139 
patients
Usual Care Group
Hospital 
Stroke Unit
Home
Nursing Home
Rehabilitation 
Centre
Ultimate Destination 
(Home,Resident Home, 
Nursing Home)Heijnen et al. BMC Public Health 2010, 10:279
http://www.biomedcentral.com/1471-2458/10/279
Page 4 of 9
1. Rehabilitation at home with outpatient care pro-
vided by therapists from primary healthcare or day
care rehabilitation in a hospital or nursing home
2. Inpatient rehabilitation in a nursing home
3. Inpatient rehabilitation in a rehabilitation centre
Usual care
The redesigned stroke service provided by the Stroke Ser-
vice Maastricht Heuvelland, the intervention region, will
be compared to "care as usual" provided by the stroke ser-
vice in the Eindhoven area.
In the Stroke Service Eindhoven stroke patients are
admitted to the stroke unit of the Catharina hospital in
Eindhoven, where diagnostic tests, treatment and obser-
vation take place. During the patients' stay in the hospital,
an assessment is performed in order to determine the
best suitable rehabilitation facility for the stable patient.
A physiotherapist, an occupational therapist and trained
nurses carry out the assessment; if necessary they are
supported by a speech therapist or a psychologist.
On the basis of admission and discharge criteria formu-
lated by the various care providers who participate in the
Stroke Service Eindhoven, the patient can be discharged
to home, to a rehabilitation centre or to one of four nurs-
ing homes participating in the stroke service. The mean
duration of the hospital stay in Eindhoven is 10 days.
Consequently, the main differences in care arrangements
between the experiment and the control region are the
early hospital discharge and the structured assessment in
the nursing home.
Effect evaluation
The primary outcome measures of the effect evaluation
are quality of life and activities of daily life (ADL). Quality
of life is measured by means of the Stroke Adapted Sick-
ness Impact Profile 30 (SA-SIP 30)[12] and ADL by
means of the Barthel index (BI)[13,14].
Secondary outcome measures are: instrumental activi-
t i e s  o f  d a i l y  l i v i n g  ( I A D L )  m e a s u r e d  b y  m e a n s  o f  t h e
Frenchay Activity Index (FAI)[15], handicap measured by
means of the Modified Rankin Scale (MRS)[16]. Cogni-
tive functioning is measured by means of Mini Mental
State Examination (MMSE)[17], Apraxia Test (AT)[18]
and Star Cancellation Test (SCT)[19]. Anxiety and
depression are measured by the Hospital Anxiety and
Depression Scale (HADS)[20] and the patients' satisfac-
tion with stroke care is measured by means of the Satis-
faction with Stroke Care Questionnaire (SASQ-19)[21].
The strain on caregivers is measured by the Caregivers
Strain Index (CSI)[22].
Other secondary outcome measures are medical com-
plications occurring within 3 months after stroke. The
following diagnoses are regarded as medical complica-
tions: a new stroke, epileptic seizures, pneumonia, uri-
nary tract infections, fractures, bedsores, myocardial
infarct, heart failure and atrial fibrillation. The data on
medical complications will be collected from the patients'
files.
Besides the primary and secondary outcome measures
we assess some background variables which are consid-
ered to be predictors, confounders or effect modifiers.
The following personal characteristics are assessed: age,
sex, socio-economic status, risk factors, co-morbidity,
s t r o k e  l o c a t i o n  a n d  s t r o k e  s e v e r i t y  m e a s u r e d  b y  t h e
National Institute of Health Stroke Scale (NIHSS)[23]. All
background variables are measured at baseline.
Economic evaluation
The economic evaluation compares costs and outcomes
of stroke care given in the Stroke Service Maastricht Heu-
velland to care as usual provided by the Stroke Service
Eindhoven. The economic evaluation will involve a com-
bination of a cost-effectiveness analysis (CEA) and a cost-
utility analysis (CUA). In a CEA effects are presented in
clinical outcomes.
The primary outcome measure of the cost-effectiveness
analysis will be the SASIP-30. Within the cost-utility
analysis, outcomes will be measured by means of the
standard Dutch version of the EuroQol (EQ-5 D)[24].
This is a self-administered questionnaire, which will be
completed together with the cost questionnaire at 12
weeks and 26 weeks.
Both generic quality of life, as well as utilities, will be
derived by means of the EQ-5 D. The EQ-5D is chosen
because it is a widely used quality of life instrument. The
EQ-5D contains 5 dimensions of health-related quality of
life; mobility, self-care, daily activities, pain/discomfort
and anxiety/depression. Each can be rated at three levels:
no problems, some problems and major problems. The 5
dimensions can be added to comprise an overall health
state. This health state will be translated into a number, a
utility. Utility values can be calculated for these health
states, using preferences elicited from a general popula-
tion, the so-called Dolan algorithm[25]. The utility values
derived from the Dolan algorithm will be used to com-
pute Quality Adjusted Life Years (QALYs). The Dolan
algorithm has been established using a general popula-
tion from the UK. Recently a Dutch algorithm has
become available, and this will be used in the sensitivity
analysis[26]. The utilities at the two time points are used
to compute a Quality Adjusted Life Years (QALY) score
by means of the area under the curve method. Further-
more, the EQ-5D consists of a visual analogue scale
(VAS) ranging from zero (worst imaginable health state)
to 100 (best imaginable health state). The reliability and
validity of the EQ-5D has been established[27]. The pri-
mary outcome measure for the cost-utility analysis will be
Quality Adjusted Life Years (QALYs), based on the Euro-Heijnen et al. BMC Public Health 2010, 10:279
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Qol utility scores[24,27]. In the CUA, the incremental
cost-effectiveness ratio (ICER) will be expressed as the
incremental costs per QALY. This economic evaluation
will be performed from a societal perspective, which
implies that all relevant costs and outcomes will be taken
into account.
Process evaluation
The process evaluation consists of two parts. The first
part of the process evaluation consists of assessing
whether care after the redesign was performed in the
time planned. For this part of the process evaluation, the
patients' files will be screened for protocol violations
related to the discharge time from hospital, according to
protocol, and the duration of assessment in the nursing
home. If possible the reasons for these protocol violations
will be collected from the patients' files as well.
The second part assesses how patients, their personal
caregivers and professionals experience care after the
redesign. Data will be collected from 20 patients and
from their personal caregivers. Data will also be collected
from 20 professionals working in the redesigned care sys-
tem. The data will be collected by means of semi-struc-
tured in-depth interviews. The patients and professionals
will be selected by means of purposeful sampling, to
ensure that the interviewees are heterogeneous on rele-
vant determinants such as age, severity of disease, level of
functioning, housing situation (living alone, stairs, etc.).
The patients will be interviewed at home or in the institu-
tion were they are being cared for.
To ensure the open character of the interviews they will
be held by a person who is not related to the direct proj-
ect group. All interviews will be audiotaped and tran-
scribed verbatim.
Instruments
The instruments used in this study are shown in Table 1
Stroke Adapted Sickness Impact Profile 30 (SA-SIP30)
The Stroke Adapted Sickness Impact Profile measures
sickness specific quality of life in stroke patients and is a
modified version of the 136-item SIP. This instrument
was developed primarily to overcome the length of the
original SIP, which is its major disadvantage. The SA-
SIP30 is a 30-question instrument with eight subgroups,
created by eliminating the most irrelevant questions from
the initial test. The higher the score the lesser the quality
of life after stroke[12].
Barthel index (BI)
The Barthel index is a generic questionnaire which con-
sists of 10 items measuring activities of daily life (ADL)
and mobility. A high score on the Barthel index corre-
sponds with a high degree of independence concerning
the activities of daily life[13,14].
Frenchay Activities Index (FAI)
The Frenchay Activities Index is a stroke specific instru-
ment to assess functional status. The FAI is comprised of
15 items, each concerning an activity that requires some
decision making and organisation on the part of the
patient[15].
Modified Rankin Scale (MRS)
The Modified Rankin Scale is a widely used instrument
that measures levels of handicap. It defines 6 levels of dis-
ability, ranging from 0 (no symptom) to 5 (severe disabil-
ity, bedridden, incontinent and receiving constant
nursing care and attention)[16].
Mini Mental State Examination (MMSE)
The mini mental state examination is the most widely
used instrument to screen for cognitive dysfunction. The
MMSE assesses orientation, memory, attention, lan-
guage, and constructive functions. The MMSE consists of
20 items with a maximal total score of 30[17].
Apraxia Test (AT)
The Apraxia Test is a short and easy test to measure the
degree of apraxia in stroke patients. It consists of two
subtests, one designed to evaluate the use of objects and
another to evaluate the ability to imitate gestures. The
maximum score for the total test is 90[18].
Star Cancellation Test (SCT)
The Star Cancellation Test is the most sensitive single test
for neglect. Depending on the number of missed stars the
magnitude of neglect can be measured[19].
Hospital Anxiety and Depression Scale (HADS)
The Hospital Anxiety and Depression scale was devel-
oped to identify anxiety and depression among patients.
It is divided into an anxiety subscale and a depression
subscale, each containing seven intermingled items. The
maximum score is 47. The higher the score the greater
the possibility of anxiety or depression[20].
Satisfaction with Stroke Care Questionnaire 19 (SSCQ-19)
The 19-item version of the satisfaction with stroke care
questionnaire is comprised of eight items measuring sat-
isfaction with inpatient stroke care, and eleven items
measuring satisfaction with stroke care after dis-
charge[21].
Caregivers Strain Index (CSI)
The Caregivers Strain Index is a 13-item instrument that
ascertains strain on care givers across domains of
employment, finances, physical health, and social rela-
tionships. A positive answer to 7 or more of the items
reflects a more than average strain on caregivers[22].
The National Institute of Health Stroke Scale (NIHSS)
The National Institute of Health Stroke Scale provides a
measure of severity of symptoms associated with cerebral
strokes. It measures level of consciousness, visual fields,
motor response, sensation, language and neglect on
weighted scales. The NIHSS can be used with persons ofHeijnen et al. BMC Public Health 2010, 10:279
http://www.biomedcentral.com/1471-2458/10/279
Page 6 of 9
all ages, including geriatric patients, who have had a
stroke[23]. The higher the score, the more severely
affected is the patient.
European Quality of Life instrument (EuroQol)
The European Quality of life instrument (EuroQol) is a
well-known generic instrument measuring health-related
quality of life. It includes 5 dimensions (mobility, self-
care, daily activities, pain/discomfort and anxiety/depres-
sion) and a visual analogue scale that evaluates patients'
perceived health status[24]. Each dimension can be rated
at three levels: no problems, some problems and major
problems. The 5 dimensions can be summarized in a
health state.
Cost Questionnaire
We will assess intervention costs, healthcare costs,
patient and family costs, and costs outside the healthcare
sector. For this study we will develop a cost questionnaire
especially designed for this group, based on existing
questionnaires[28,29], which identify all relevant costs
aspects.
Effect analysis
For the analyses we will use SPSS statistical software and
Excel (for the Bootstraps). Missing data on the item level
will be handled using SPSS missing value analysis. If con-
siderable data are missing related to specific instruments,
imputation will be considered.
A baseline analysis will be performed to examine the
comparability of groups at baseline for both costs and
outcomes. If necessary, methods will be applied to cor-
rect for differences in baseline[30]. A Kolmogorov-
Smirnov test will be performed to investigate whether the
data are normally distributed. If the data are distributed
normally, our primary analysis will start with a t-test. If
data are skewed, the primary analysis will be based on a
non-parametric test for assessing two independent sam-
ples, i.e. a Mann-Whitney U test.
As it is known that in non-randomised comparative
studies, variations in case mix between centres can influ-
ence the interpretation of outcome data[31], we would
like to explore this in further analysis. Therefore, for each
of the data sets collected at all measurement points, dif-
ferences in outcome variable between the 2 regions will
be tested using multiple MANCOVAs, entering various
indicators of case mix as co-variates, i.e. age, gender,
stroke severity. In addition, information on possible con-
founding factors and effect modifiers will be collected
and analysed.
Economic analysis
Total costs will be estimated using a bottom-up (or
micro-costing) approach, where information on each ele-
ment of service used is multiplied by an appropriate unit
cost and these are added to provide an overall total
cost[32]. We will assess intervention costs, healthcare
costs, patient and family costs, and costs outside the
health care sector. For this study we will use a cost ques-
tionnaire especially designed for this group, based on
existing questionnaires[28,29], which will identify all rele-
vant cost aspects.
Table 1: Overview of instruments per time point
Time after stroke
Instrument T0 T1 T2 T3
< 1 week 4 Weeks 12 Weeks 26 Weeks
SA-SIP30 XX
B a r t h e l  i n d e xX XXX
Frenchay Activities Index X X
M o d i f i e d  R a n k i n  S c a l e X XXX
Mini Mental State Examination X X
Apraxia Test X X
Star Cancellation Test X X
Hospital Anxiety and 
Depression scale
XX
SASC-19 After every discharge
Caregivers Strain Index X
EQ-5D XX
Cost Questionnaire X X
Instruments used for the screening process, the clinical outcome assessment and the economic evaluation. In Table 1 an overview of all 
assessments per time point is shown.Heijnen et al. BMC Public Health 2010, 10:279
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To measure the actual use of resources, data will be
obtained using combined sources (registrations by pro-
fessionals and cost questionnaire). Resources used relat-
ing to the interventions will be an estimation of the time
spent by the professionals, based on prospective registra-
t i o n  i n  a  r a n d o m  s a m p l e .  A l l  u s e  o f  r e s o u r c e s  b y  t h e
patient and their family, in and outside the health care
sector, will be measured by means of a cost questionnaire,
in which the resource utilization is recorded at 12 weeks
and 26 weeks during the follow-up period. These sources
of information will be combined.
The valuation of healthcare costs and costs to patient
and family will be based on the updated Dutch manual
for cost analysis in healthcare research[33,34]. This man-
ual recommends using standardized cost prices. In brief,
the manual recommends that prices of informal care will
be based on shadow prices for unpaid work (meaning a
standard cost price based on general hourly wages). Costs
of transport will be calculated as the mean distance per
destination multiplied by standard cost prices. Costs of
medication will be calculated using prices based on Daily
Defined Dosage (DDD) taken from the Dutch Pharmaco-
therapeutic Compass[35], indicating the mean medica-
tion usage per adult per day. Productivity costs will be
calculated by means of the friction costs method, based
on a mean added value of the Dutch working population.
The friction costs method takes into account production
losses confined to the period needed (usually 90 days) to
replace a sick employee. In case of uncertainty we will use
a conservative estimation (i.e. the lowest cost price). Cost
prices will be expressed in 2010 euros. If necessary, exist-
ing cost prices will be updated to 2010 using the con-
sumer price index (CPI)[33,34].
Despite the usual skewness in the distribution of costs,
arithmetic means are generally considered the most
appropriate measure to describe cost data[36,37]. There-
fore, arithmetic means (and standard deviations) will be
presented. In case cost data are skewed, non-parametric
bootstrapping will be used to test for statistical differ-
ences in costs between the intervention and control
group. Non-parametric bootstrapping is a method based
on random sampling with replacement based on the indi-
vidual data of the participants[38]. The bootstrap replica-
tion will be used to calculate 95% confidence intervals
around the costs (95% CI), based on the 2.5 th and 97.5 th
percentiles. If cost data are distributed normally, t-tests
will be used.
The incremental cost effectiveness ratio (ICER) will be
determined on the basis of incremental costs and effects
of the intervention compared to care as usual. The cost
effectiveness ratio will be stated in terms of costs per out-
come rate; the cost utility ratio will focus on the net cost
per QALY gained.
The ICER will be calculated as follows. ICER = (Ci-Cc)/
(Ei-Ec), where Ci represents the total costs of the inter-
vention group at the 26-weeks follow-up, Cc the total
costs of the care as usual group at the 26-weeks follow-
up, Ei the effects at the 6-month follow-up for the inter-
vention group and Ec the effect at the 26-weeks follow-up
for the care as usual group. The robustness of the ICER
will be checked by non-parametric bootstrapping (1000
times). Bootstrap simulations will also be conducted in
order to quantify the uncertainty around the ICER, yield-
ing information about the joint distribution of cost and
effect differences. The bootstrapped cost-effectiveness
ratio will be plotted subsequently in a cost-effectiveness
plane, in which the vertical line reflects the difference in
costs and the horizontal line reflects the difference in
effectiveness.
The choice of treatment depends on the maximum
amount of money that society is prepared to pay for a
gain in effectiveness, which is called the ceiling ratio.
Therefore, the bootstrapped ICERs will also be depicted
in a cost effectiveness acceptability curve showing the
probability that the intervention care is cost effective
using a range of ceiling ratios.
Process evaluation analysis
The process evaluation will be analysed mainly by means
of qualitative data analysis. The interviews will be analy-
sed by directed content analysis[39]. After identifying and
coding text passages relevant to the research question,
the descriptive codes will be compared and contrasted by
sequential and retrospective searching within and among
the interviews. The codes will be grouped into larger
themes, explored further, structured, refined and reduced
in number. Data will be collected and analysed concur-
rently, allowing both expected and emergent themes and
ideas to be incorporated and explored in subsequent
interviews. Units of text referring to similar codes will be
grouped and categorized systematically by one central
coder, who is coding all the interviews. For the richest
interviews - in the opinion of the interviewer - a full open
coding of the transcript will be independently executed
by the central coder and the interviewer. Differences in
coding will be resolved by consensus discussion face-to-
face or by phone. The central coder will then analyse the
other interviews in the subset of interviews done by the
one interviewer, and the interviewers will check the cod-
ing.
Discussion
Implementation of the redesigned stroke care pathway in
the Stroke Service Maastricht Heuvelland started in 2006.
It has yet to be seen whether the introduction of this care
pathway has led to improvement of the quality of care for
stroke patients. The results of this study will provideHeijnen et al. BMC Public Health 2010, 10:279
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information about the cost effectiveness of the interven-
tion and its effects on clinical outcomes and quality of
life. In this respect the relevance of this study lies in the
fact that it is one of the first studies assessing the cost
effectiveness of a stroke service from a societal point of
view. In case of proven cost effectiveness, arguments for
implementing the intervention into usual healthcare are
clear and evident.
A weak point of this study is the possible bias of non-
randomisation. In our study randomisation is impossible
as the location of the stroke patient necessarily deter-
mines to which hospital the patient will be admitted, and
in order to prevent contamination effects, only one treat-
ment will be offered in one hospital. If our intervention
appears to be cost effective, the next step will be broader
implementation in more nursing homes. In addition, it
will be possible to perform a cluster randomised trial to
obtain even more evidence on the effectiveness of the
interventions. A strong point of the study is the stan-
dardised and consequent use of validated measurement
instruments, which make the characteristics of the study
population accessible for further studies.
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